BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL

Jennifer Woyach, MD, Discusses BRUIN CLL-322 Design, Enrollment ProcessПодробнее

Insights into the BRUIN CLL-322 trialПодробнее

BRUIN study update: analysis of the mechanisms of resistance to pirtobrutinib in CLLПодробнее

MAIC of pirtobrutinib vs venetoclax continuous monotherapy in patients with R/R CLLПодробнее

Pirtobrutinib vs nemtabrutinib in CLLПодробнее

The promise of pirtobrutinib in the treatment of CLLПодробнее

Some insights into BRUIN CLL-322: a trial in progressПодробнее

BRUIN CLL-322 update: fixed-duration pirtobrutinib plus VR vs VR in patients with R/R CLLПодробнее

Pirtobrutinib in CLL: updates from the BRUIN CLL-321 trialПодробнее

Genomic evolution & resistance to pirtobrutinib in covalent BTK inhibitor pre-treated CLLПодробнее

Acalabrutinib vs ibrutinib in R/R CLL: assessing the burden of adverse eventsПодробнее

Dr. Coombs on Second Generation BTK Inhibitors for CLLПодробнее

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclaxПодробнее

BRUIN MCL-321: pirtobrutinib vs investigator choice of BTK inhibitor in BTK inhibitor-naive MCLПодробнее

BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLLПодробнее

Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trialПодробнее

BRUIN study cohort update: pirtobrutinib for patients with MCLПодробнее

Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023Подробнее

Pirtobrutinib for BTK inhibitor-naïve and BTK inhibitor pre-treated R/R MCLПодробнее